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Recent studies suggest a link between mitochondria and proinﬂammatory cytokine generation. We
previously demonstrated that overexpression of mitochondrial chaperone glucose-regulated pro-
tein75 (Grp75/mortalin) protects mitochondria. In this study we investigated the modulation of
the lipopolisaccharide (LPS)-induced inﬂammatory response of microglial BV-2 cells by Grp75. We
demonstrate that LPS-induced activation promotes signiﬁcant metabolic changes suppressing mito-
chondrial function and increasing glycolysis. Overexpression of Grp75 attenuates the LPS-induced
oxidative and metabolic responses, and suppresses proinﬂammatory activation, which depends
on both NF-jB activation and lactate. Thus overexpression of Grp75 provides a novel strategy to
modulate proinﬂammatory cytokine production of relevance to inﬂammation-associated
pathologies.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction [10], there is also evidence thatmitochondrialmetabolism is impor-Many chronic human diseases, including neurodegenerative dis-
orders, are associatedwith inﬂammation. These diseases are charac-
terizedby excessive reactive oxygen species (ROS) production [1–3].
Mitochondrial impairment has also been implicated in these disor-
ders [4,5],withmitochondriabotha sourceofROSandacriticalorga-
nelle that is the target of ROSdamage.Mitochondrial ROS canact as a
major trigger of proinﬂammatory cytokine production. Nakahira
et al. and Zhou et al. used antioxidants, genetic models, and inhibi-
tors of mitochondrial function to demonstrate that inﬂammatory
stimuli lead to increasedmitochondrial ROS production, that in turn
induces inﬂammasome activation [6,7]. ROS generated by mito-
chondrial function were shown to be important for lipopolysaccha-
ride (LPS)-induced production of proinﬂammatory cytokines [8].
Mitochondrial densityand/or respiratoryactivitywere found to con-
tribute to LPS-induced proinﬂammatory cytokine release frommac-
rophages in a recent study that used a q0 macrophage cell line that
lacks mitochondria [9].
While the connection between mitochondrial ROS production
and proinﬂammatory cytokine generation is now well establishedtant for the anti-inﬂammatory program of macrophage activation
[11]. In their studyVatset al. suggested thatglycolysispromotespro-
inﬂammatory activation ofmacrophages, whereas oxidativemetab-
olism primes macrophages for a less-inﬂammatory mode of
activation [11]. The importance of a metabolic switch to glycolysis,
throughHIF-1-associatedmechanisms, during the inﬂammatory re-
sponses of myeloid cells has been demonstrated in earlier studies
[12,13]. Glycolyticmetabolism is also associatedwith increased lev-
els of lactate production [14]. It has been reported that lactate en-
hances LPS-stimulated proinﬂammatory macrophage activation
[15]. This lactate-associated proinﬂammatory boost is mediated
through nuclear factor-jB (NF-jB) [16], a pivotal transcription
factor in inﬂammatory response [17]. Overall, the involvement of
mitochondrial metabolism per se in pro-inﬂammatory cytokine
production has not been extensively investigated.
In our previous studies we showed that overexpression of mito-
chondrial glucose-regulated protein 75 (Grp75/mtHsp70/mortalin)
leads to decreased ROS production, preservation of mitochondrial
membrane potential, and preservation of ATP production in the face
of ischemic injury both in vivo and in vitro [18,19]. This is consistent
with a previous study that demonstrated protection of ATP levels,
mitochondrial function, and reduced ROS accumulation during glu-
cose deprivation in neuronal cells overexpressing Grp75 [20]. The
purpose of this studywas to investigatewhether Grp75 overexpres-
sion downregulates LPS-induced mitochondrial ROS production in
microglial BV-2 cells, and whether this downregulation reduces
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metabolic shifts induced during LPS-stimulation, their modulation
by Grp75 overexpression, and the importance of these metabolic
changes in the proinﬂammatory response of BV-2 cells.
2. Materials and methods
2.1. BV-2 cells and Grp75 overexpression
BV-2 murine microglia were plated on uncoated plastic tissue
culture plates and grown in DMEM supplemented with 10% FBS,
and 100 U/ml penicillin and 100 lg/ml streptomycin. The macro-
phage speciﬁc mouse LysM promoter was cloned from C57BL/J6
mouse genomic DNA by PCR using the following primers: CTGA-
GAGGTCCCAAGTTCAATC and GGTGACTGGAGGCTGGGTCAGC. The
product was cloned into pCR2.1 using a TOPO-TA kit (Invitrogen,
Carlsbad, CA) and excised by HindIII and XhoI. It was subcloned
into pAcGFP1-1 (Clontech, Mountain View, CA). The resulting con-
struct LysM–GFP was used as a control plasmid in all transfection
experiments. The human Grp75 coding sequence in pBluescript
[21] was a generous gift from R. Morimoto at Northwestern Uni-
versity. To produce LysM–Grp75 the Grp75 coding sequence was
excised by NotI and SalI, and inserted into the control LysM–GFP
plasmid after removing the GFP sequence with the same enzymes.
BV-2 cells were plated in 24-well plates one day before transfec-
tion with LysM–Grp75 or LysM–GFP (control) plasmids, using Lipo-
fectamine reagent (Invitrogen). Successfully transfected BV-2 cells
were selected in 400 lg/ml G418 (Sigma) for 4 weeks, then exper-
iments were performed on essentially conﬂuent cultures of BV-2
cells in which essentially all cells stably expressed Grp75, or con-
trol GFP protein. Three independently derived stable cell lines were
used in the study. For LPS treatment BV-2 cells were rinsed once
with DMEM then incubated for 3 h in DMEM with added LPS
(1 lg/ml, Sigma, St Louis, Missouri). When added, trolox + edarav-
one (100 lM each) and oligomycin (10 lM) were applied simulta-
neously with LPS for the duration of treatment.
2.2. Live imaging
Cells were incubated with the mitochondrial ROS sensitive dye
MitoSox (Invitrogen, Carlsbad, CA) according to the manufacturer’s
instructions beginning at 2 h of LPS treatment for 1 h (total 3 h LPS
treatment) before ﬂuorescence measurements. We found that Mit-
oSox ﬂuorescence measurements need to be performed within a
short time after the initial dye incubation to avoid migration of
the MitoSox signal to other cellular, particularly nuclear, locations.
Cells were illuminated at 535 nm, and ﬂuorescence emission was
observed at 590 nm using an Axiovert 200 M ﬂuorescence micro-
scope (Carl Zeiss, Jena, Germany). Several ﬁelds/condition were se-
lected at random using phase-contrast optics, and the intensity of
six ﬁeld of view areas (approximately 100 cells/area) were ana-
lyzed to produce the average intensity reading for each well.
2.3. Western blot analysis
Western blot analysis was performed as previously described
[18]. The Grp75 band intensity was normalized to the actin band
intensity in the same lane.
2.4. TNF-a, IL-6, and lactate measurements
After 3 h of LPS treatment (1 lg/ml) the media from LPS-treated
or control DMEM-treated BV-2 cells was collected. Levels of proin-
ﬂammatory cytokines were determined by ELISA TNF-a and IL-6
kits (Invitrogen, Carlsbad, CA).2.5. Measurements of oxygen consumption rates, lactate and ATP
levels
Real-time measurements of oxygen consumption rates, and
extracellular acidiﬁcation rates, a measure of lactate production,
were performed on an XF24 Seahorse extracellular ﬂux analyzer
(Seahorse Biosciences) according to manufacturer’s instructions
and as previously described [22]. Lactate levels were also indepen-
dently estimated using the Lactate Assay Kit (Biovision Research,
Mountain View, CA). Cell lysate protein concentrations were mea-
sured with the BCA protein assay reagent kit (Pierce, Rockford, IL).
Cellular ATP concentrations after 3 h of LPS treatment were mea-
sured using the CellTiter-Glo luminescent ATP assay kit (Promega,
Madison, WI), based on the luciferase/luciferin reaction. A Veritas
luminescence counter (Turner BioSystems, Sunnyvale, CA) was
used to measure the luminescence signal.
2.6. In vitro immunocytochemistry and functional assay of NF-jB
translocation
Fluorescence immunocytochemistry was performed using pri-
mary anti-Grp75 antibody (1:300, Stressgen, Ann Arbor, MI) and
secondary Alexa Fluo 488-conjugated secondary antibodies
(1:200, Invitrogen) as previously described [18]. Co-staining with
the mitochondrial speciﬁc dye MitoTracker Red (Invitrogen, Carls-
bad, CA) was used to conﬁrm mitochondrial localization of Grp75.
To assess the accumulation of NF-jB in 4060-diamidino-2-phenylin-
dole (DAPI)-stained nuclei we used antibody to Rel A (p65) subunit
(sc-109, Santa Cruz Biotechnology, Santa Cruz, CA) followed by
staining with secondary AlexaFluo 488-conjugated secondary anti-
body (1:200, Invitrogen). NF-jB consists of two subunits, p65 (Rel
A) and p50 (NF-jB1), and is present in the cytoplasm in an inactive
form, complexed with inhibitor of NF-jB (IjB). In response to pro-
inﬂammatory activators, NF-jB dissociates from IjB and translo-
cates from the cytoplasm to the nucleus, with subsequent binding
to genes containing the jB site [23]. We evaluated the intensity of
NF-jB ﬂuorescent staining within the area of the cell nuclei in
comparison to cytoplasmic staining using the DAPI nuclei images
of the same area. In addition, NF-kB activation was quantitated
using the TransAM NF-kB Activation Assay (Active Motif, Carlsbad,
CA), according to the manufacturer’s instructions. We also used a
speciﬁc NF-jB inhibitor BAY11-7085 (Santa Cruz Biotechnology,
Santa Cruz, CA).
2.7. Statistics
Statistical differences between two groups were determined
using unpaired two-tailed Student’s t-test with Welch’s correction.
Comparisons between multiple groups were performed with ANO-
VA followed by Bonferroni test for selected groups. Data in all plots
are pooled from three independent experiments and presented as
mean ± S.D.3. Results
3.1. Overexpression of Grp75 in BV-2 cells
Previous studies from our laboratory and others revealed
endogenous Grp75 expression in various brain cell types [18,24].
The established Grp75 overexpressing BV-2 cell line demonstrated
markedly higher levels of Grp75 expression compared to GFP-over-
expressing control cells, as indicated by Western blot (Fig. 1A). In-
creased Grp75 overexpression and preferential mitochondrial
localization were conﬁrmed by immunocytochemistry (Fig. 1B
and C).
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We used MitoSox, a ﬂuorescent indicator of mitochondrial ROS
production to investigate the effect of LPS treatment on the levels
of mitochondrial oxidative stress in control and Grp75-over-
expressing cells. As shown in Fig. 2A and B, there was no signiﬁcant
difference in the levels of mitochondrial ROS in non-stimulated
control and Grp75-overexpressing BV-2 cells. LPS treatment
caused a 3.6-fold increase in the levels of MitoSox ﬂuorescence
in control BV-2 cells (Fig. 2C), while Grp75-overexpressing cells
demonstrated only a 2.6-fold increase of MitoSox signal (Fig. 2D),
signiﬁcantly lower. We then used a combination of Trolox, a water
soluble vitamin E analog and a powerful antioxidant [25], and a
free radical scavenger edaravone [26] to suppress LPS-induced
mitochondrial ROS generation. As demonstrated in Fig. 2E and F,
the trolox + edaravone antioxidant treatment resulted in suppres-
sion of LPS-induced mitochondrial ROS down to the basal levels
observed in non-stimulated cells. In some of our experiments, in
order to investigate the effects of Grp75 overexpression on pro-
inﬂammatory activation of BV-2 cells, we used mitochondrial
inhibitors to block mitochondrial function. Among different mito-
chondrial inhibitors and uncouplers tested (rotenone, antimycin
A, oligomycin, FCCP) only oligomycin did not increase mitochon-
drial ROS levels in LPS-treated cells in the presence of trolox + eda-
ravone (Fig. 2G and H), or under other studied conditions (both
with and without LPS), and was therefore used in further experi-Fig. 1. Grp75 overexpression in BV-2 cells. (A) Expression levels of Grp75 in control
and Grp75 overexpressing cells as determined by Western blot (⁄P < 0.05). (B)
Immunohistochemical Grp75 staining of control and Grp75 overexpressing BV2
cells. The data are representative of three independently derived stable cell lines.
(C) Co-localization of immunohistochemical Grp75 staining and mitochondrial
marker MitoTracker Red.
Fig. 2. Mitochondrial ROS generation induced by LPS and its modulation by
antioxidants and oligomycin. Representative images of control and Grp75 over-
expressing BV-2 cells loaded with MitoSox under control conditions (A and B).
Images after treatment with LPS (C and D), LPS with trolox + edaravone (100 lM
each; TE) co-treatment (E and F), and LPS + TE + oligomycin (10 lM; G and H).
Quantiﬁcation of changes in mitochondrial ROS induced by LPS and co-treatments
with TE and oligomycin assessed as MitoSox ﬂuorescence (I). The data show the
means of three independent experiments, with at least 150 cells per condition in
each experiment (⁄P < 0.05, #P < 0.05 compared to all other control treatment
groups, and ##P < 0.05 compared to all other Grp75 overexpressing treatment
groups).
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conditions is summarized in Fig. 2I.
3.3. Effect of Grp75 overexpression on TNF-a and IL-6 levels
To determine the effect of Grp75 overexpression on proinﬂam-
matory BV-2 activation we measured levels of the inﬂammatory
cytokines TNF-a and IL-6. As demonstrated in Fig. 3A, LPS treatment
induced high levels of TNF-a production in both control and Grp75
overexpressing BV-2 cells (6.4 and 4.7 ng/ml, respectively), though
signiﬁcantly lower in the Grp75 overexpressors. Elimination of
mitochondrial ROS production with trolox + edaravone resulted in
a signiﬁcantdecrease inTNF-aproduction incontrol cells, consistent
with prior literature [10], and a trend to lower levels of TNF-a pro-
duction inGrp75overexpressing cells (P = 0.054). Importantly, a sig-
niﬁcant difference in the LPS-induced levels of TNF-a was still
observed between control and Grp75-overexpressing cells even
when mitochondrial ROS production was eliminated. This suggests
that in addition to effects of ROS, other aspects of mitochondrial
function contribute to theobserveddifferences in TNF-aproduction.
To assess the importance of mitochondrial metabolic function in
determining the ability of Grp75 to exert its anti-inﬂammatory ef-
fect we inhibitedmitochondrial metabolismwith oligomycin. Elim-
ination of mitochondrial ROS (see Fig. 2G) in combination withFig. 3. Effects of antioxidants and mitochondrial inhibition with oligomycin on LPS-
induced increases in proinﬂammatory cytokines in control and Grp75 overexpress-
ing cells. LPS treatment increased levels of TNF-a (A) and IL-6 (B) as assessed by
ELISA. These levels were affected by addition of the antioxidant trolox + edravone
(TE), and the combined addition of TE and the mitochondrial inhibitor oligomycin.
The data show the means of three independent experiments, with two samples per
condition in each experiment, for both TNF-a and IL-6 (⁄⁄P < 0.01, ⁄⁄⁄P < 0.001).inhibitionofmitochondrial functionbyoligomycinequalizedLPS in-
duced TNF-a production in control and Grp75-overexpressing BV-2
cells. Thus inhibition of mitochondrial function had the expected
pro-inﬂammatory effect increasing TNF-a production in the Grp75
overexpressing cells, and eliminating the difference in the levels of
cytokineproductionbetween the control andGrp75-overexpressing
cells, indicating the contribution of a mitochondrial metabolic
mechanism of Grp75-associated modulation of TNF-a production.
Similar results were obtained in measurements of IL-6 levels, as
demonstrated in Fig. 3B.
3.4. Effect of Grp75 overexpression on LPS-induced changes in BV-2
cell metabolism
We next investigated metabolic changes in control and Grp75
overexpressing BV-2 cells. Fig. 4A demonstrates that LPS treatment
signiﬁcantly decreased ATP levels in control, but not in Grp75-over-
expressing cells. No other treatments resulted in signiﬁcant changes
in ATP. Fig. 4B shows that LPS treatment signiﬁcantly suppressed
oxygen consumption rate, an indicator ofmitochondrial respiration,
in both control and Grp75 overexpressing cells, but the suppression
was signiﬁcantly higher in control cells. The LPS-induced changes in
oxygen consumption were not signiﬁcantly modulated by trol-
ox + edaravone antioxidant treatment in either cell type. As ex-
pected, oligomycin treatment strongly suppressed mitochondrial
oxygen consumption rates. Because some cell types can compensate
for reduced mitochondrial ATP production by increased glycolytic
activity through Pasteur effect-like mechanisms [27], we measured
changes in lactate levels as a measure of glycolytic activity [28]. We
used both a lactate assay kit (see Supplementary Fig. 1) and made
Seahorse real-timemeasurementsof extracellularacidiﬁcationrates
as ameasureof lactate levels (see Section2),with similar results. The
real-timemeasurements provided amore pronounced difference in
lactate production between the different groups, as we found that
lactate differences were attenuated at longer treatment times.
Fig. 4C shows that LPS treatment caused a signiﬁcantly greater in-
crease in lactate levels in control compared toGrp75 overexpressing
cells. The reduced rates of oxygen consumption and increased lac-
tate production indicate a metabolic shift to glycolytic ATP produc-
tion to partially or fully compensate for reduced mitochondrial
ATP production. The LPS-induced changes in lactatewere not signif-
icantlymodulated by the trolox + edaravone antioxidant treatment;
a signiﬁcant difference remained in the levels of lactate production
betweenGrp75overexpressingandcontrol cells. Further, essentially
complete inhibition of mitochondrial function by oligomycin pro-
moted a signiﬁcant increase in lactate levels and eliminated the dif-
ference in the rates of lactate production between control andGrp75
overexpressing cells. Since it was proposed that increased lactate
levels enhance the LPS-induced production of proinﬂammatory
cytokines [15], we investigated the effect of sodium lactate (5 mM)
co-treatment in control and Grp75 overexpressing BV-2 cells ex-
posed to LPS and trolox + edaravone. Sodium lactate addition re-
sulted in a signiﬁcant increase in both TNF-a and IL-6 levels,
comparable to or exceeding those induced by oligomycin co-treat-
ment (see Fig. 4A and B). The addition of 5 mM sodium lactate, in
addition to LPS + trolox + edaravone, resulted in 7.8 ± 0.53 and
8.0 ± 0.6 (ng/mg protein) production of TNF-a (compare to Fig. 4A),
and 3.6 ± 0.61 and 3.75 ± 0.67 (ng/mg protein) of IL-6, in control
and Grp75 overexpressing cells, respectively (compare to Fig. 4B).
3.5. NF-jB activation
NF-jB activation has been shown to be a major mechanism
underlying the proinﬂammatory response of macrophages. Be-
cause it was demonstrated that cellular metabolism, and particu-
larly lactate levels, modulate macrophage activation through the
Fig. 4. LPS-induced changes in BV-2 cell metabolism. (A) ATP levels in control and
Grp75 overexpressing cells without and with LPS treatment, and LPS with addition
of antioxidant trolox + edravone (TE) treatment and LPS with TE + oligomycin to
additionally inhibit mitochondrial metabolism. (B) Oxygen consumption rate (OCR)
for the same conditions. (C) Extracellular acidiﬁcation rates (ECAR), a measure of
lactate production, is shown for both cell types for the same conditions. The data
show the means of three independent experiments, with two samples per condition
in each experiment (⁄P < 0.05, ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001).
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in control and Grp75 overexpressing cells. Fig. 5A–D shows that
LPS treatment promoted a signiﬁcant increase in NF-jB activation,
as indicated by cytoplasm-to-nucleus translocation, in control and
Grp75 overexpressing cells. Quantitative measurements of NF-jB
activation are presented in Fig. 5E. The LPS-induced NF-jB activa-
tion was attenuated by trolox + edaravone antioxidant treatment,
but a signiﬁcant difference in the levels of NF-jB activation be-
tween Grp75 overexpressing and control cells was still observed.
As in the case of TNF-a and IL-6 production, this difference
persisted despite the elimination of mitochondrial ROS withantioxidant treatment, and is apparently related to signiﬁcant dif-
ferences in cellular metabolism, particularly lactate levels (See
Fig. 4B). Inhibiting mitochondrial function by addition of oligomy-
cin eliminated the difference in the levels of NF-jB activation be-
tween control and Grp75 overexpressing cells. To conﬁrm the
involvement of NF-jB activation in the increased levels of proin-
ﬂammatory cytokine production we used a speciﬁc NF-jB inhibitor
BAY11-7085, that has been shown to completely block LPS-in-
duced IL-6 secretion by macrophages [15]. Co-treatment with
BAY11-7085 (10 lM) suppressed LPS-induced IL-6 and TNF-a lev-
els 90% and 95%, respectively, in control and Grp75 overexpressing
cells, thus conﬁrming the crucial role of NF-jB in the observed pro-
inﬂammatory cytokine production.
4. Discussion
Chronically elevated levels of proinﬂammatory cytokines, par-
ticularly TNF-a and IL-6, have been proposed to play a major role
in neurodegenerative diseases including Alzheimer’s, Parkinson’s,
stroke, dementia, and multiple sclerosis [29,30]. These neurode-
generative diseases are also characterized by increased levels of
oxidative stress and mitochondrial dysfunction [5,10]. There is
growing evidence for the involvement of both mitochondrial ROS
and mitochondrial metabolism in proinﬂammatory macrophage
activation [10]. In this study we investigated whether overexpres-
sion of mitochondrial Grp75, which was shown previously to
improve mitochondrial function and decrease oxidative stress
[18–20], was able to modulate the LPS-induced pro-inﬂammatory
response of BV-2 microglial cells.
We observed that LPS treatment promoted signiﬁcant increases
in the proinﬂammatory cytokines TNF-a and IL-6, and mitochon-
drial ROS levels, in both control and Grp75 overexpressing cells.
However, the LPS-induced increases of both ROS and cytokines
were signiﬁcantly reduced by Grp75 overexpression. We also
investigated metabolic changes induced by LPS-treatment in BV-
2 cells. We observed increased lactate production accompanied
by decreased cellular ATP levels in control BV-2 cells. These results
suggest that increased glycolysis was not sufﬁcient to compensate
for decreased mitochondrial ATP production. The LPS-induced lac-
tate increase was signiﬁcantly attenuated in Grp75 overexpressing
cells, with unchanged levels of cellular ATP, indicating a complete
compensation for decreased mitochondrial ATP production by gly-
colysis. Our observations are in line with recent studies demon-
strating a switch from oxidative phosphorylation to glycolysis,
through inducible NO synthase during inﬂammatory activation of
dendritic cells [31,32], while anti-inﬂammatory activation is asso-
ciated with preserved mitochondrial oxidative metabolism [11].
Since mitochondrial ROS have been shown to play a role in the
inﬂammatory response we compared the effect of eliminating
mitochondrial ROS on LPS-induced responses of control and
Grp75 overexpressing cells. The combination of trolox + edaravone
fully reduced mitochondrial ROS production to baseline levels, and
signiﬁcantly reduced proinﬂammatory cytokine production in both
cell types. Despite this, a signiﬁcant difference in the levels of pro-
inﬂammatory cytokine production remained in the absence of ele-
vated mitochondrial ROS between Grp75 and control cells,
indicative of an additional mechanism. It should be noted that
the trolox + edaravone combination effectively suppresses not only
mitochondrial, but overall cellular ROS. The use of more speciﬁc
mitochondrial ROS inhibitors, like mitoQ [29], would allow a more
precise investigation of the contribution of mitochondrial ROS to
the inﬂammatory response.
Metabolic measurements demonstrated a signiﬁcant difference
in the levels of lactate production between control and Grp75 over-
expressing cells. These measurements indicate that removal of
mitochondrial ROS does not completely eliminate the LPS-induced
Fig. 5. NF-jB activation induced by LPS and its modulation by antioxidants and oligomycin. Representative images of control and Grp75 overexpressing untreated BV-2 cells
(A and B). LPS treatment induced NF-jB activation indicated by nuclear localization in control cells (C) that was attenuated in Grp75 overexpressing cells (D). (E) The level of
NF-jB activation induced by LPS and co-treatments with trolox + edaravone (TE) and oligomycin was quantitated using the TransAM NF-jB activation assay. The data show
the means of three independent experiments (⁄P < 0.05, ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001).
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tween control and Grp75 overexpressing cells. The levels of NF-jB
activation, a key proinﬂammatory transcription factor, also re-
mained signiﬁcantly different between control and Grp75 over-
expressing cells, despite ROS elimination. This emphasizes that
not only mitochondrial ROS production, but metabolism per se, is
involved in the activation of proinﬂammatory mechanisms. We
propose that LPS-induced increased glycolytic activity and lactate
levels contribute to the observed pro-inﬂammatory response, as
an earlier study demonstrated a strong enhancement of LPS-in-
duced NF-jB activation and proinﬂammatory cytokine production
by elevated lactate levels [15].
To further conﬁrm the importance of mitochondrial metabolic
function we blocked mitochondrial function with oligomycin, the
inhibitor of mitochondrial complex V of the respiratory chain, in
addition to suppressing mitochondrial ROS, during LPS stimulation.
This resulted in increased and essentially equal levels of lactate
and proinﬂammatory cytokine production in Grp75 overexpress-
ing and control cells. This ﬁnding conﬁrmed the important contri-
bution of protection of mitochondrial metabolism to the anti-
inﬂammatory effect of Grp75 overexpression.
It should be noted that the microglial cell line BV-2, rather than
primary microglia, was used in our studies. While we observed
similar trends (inﬂammation-associated increased lactate produc-
tion, and Grp75-associated decrease in inﬂammatory cytokine pro-
duction) in primary isolated microglia, low transfection rates and
low post-transfection microglial survival precluded extensive met-
abolic and Grp75-overexpression studies of proinﬂammatory acti-
vation in primary microglial cells. Another limitation of this study
is that Grp75 has been shown to interact with a variety of other
mitochondrial and cellular proteins [20], thus Grp75 overexpres-
sion might potentially affect cellular function partially through
interaction with or via changed levels of these proteins.
Overall we demonstrate that LPS-induced activation of BV-2
microglial cells promotes not only excessive production of mito-
chondrial ROS, as has been reported earlier [7,8,10], but also signif-
icantly reduces ATP production and increases lactate production.
We provide evidence that overexpression of the mitochondrial
protective protein Grp75 downregulates mitochondrial ROS pro-
duction, protects mitochondrial metabolic function, suppresses
lactate production and suppresses LPS-induced proinﬂammatory
activation in BV-2 microglial cells. Our results indicate thattargeted expression of Grp75 in cells of the macrophage lineage
can provide a useful tool for investigation of the effects of sup-
pressing the inﬂammatory response in a variety of pathologies,
without directly affecting other cell types. Because suppression
of pro-inﬂammatory cytokine generation has been suggested to
be beneﬁcial in a variety of chronic diseases [33,34] our study also
suggests that Grp75 overexpression can be potentially beneﬁcial in
a variety of chronic human diseases with underlying inﬂammatory
pathologies.
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